Page 1

EXHIBIT 99.1 CORCEPT THERAPEUTICS ANNOUNCES THIRD QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE MENLO PARK , Calif . ( November 3 , 2021 ) - Corcept Therapeutics Incorporated ( NASDAQ : CORT ) , a commercial - stage company engaged in the discovery and development of drugs to treat severe metabolic , oncologic and neuropsychiatric disorders by modulating the effects of the hormone cortisol , today reported its results for the quarter ended September 30 , 2021 . . • • Financial Results Revenue of $ 96.1 million , an 11 percent increase from third quarter 2020 GAAP diluted net income of $ 0.24 per share , compared to $ 0.17 per share in third quarter 2020 Non - GAAP diluted net income of $ 0.30 per share , compared to $ 0.24 per share in third quarter 2020 Cash and investments of $ 495.2 million , compared to $ 471.6 million at June 30 , 2021 Tightening of 2021 revenue guidance to $ 365 - $ 375 million " The strong growth of our commercial business in the third quarter reflects the continued easing of COVID - related public health restrictions , ” said Joseph K. Belanoff , MD , Corcept's Chief Executive Officer . " Physicians are seeing their patients more frequently and , as a result , are better able to diagnose and treat patients with Cushing's syndrome . As pandemic conditions recede , we expect our growth to continue . Korlym is an excellent treatment for Cushing's syndrome and there are many eligible patients who have yet to receive it . " Corcept's third quarter 2021 revenue was $ 96.1 million , compared to $ 86.3 million in the third quarter of 2020. Third quarter 2021 GAAP net income was $ 30.5 million , compared to $ 21.6 million in the third quarter of 2020. Excluding non - cash expenses related to stock - based compensation and the utilization of deferred tax assets , together with related income tax effects , non - GAAP net income in the third quarter was $ 37.0 million , compared to $ 30.0 million in the third quarter of 2020. A reconciliation of GAAP to non - GAAP net income is included below . Corcept narrowed its 2021 revenue guidance to $ 365 - $ 375 million . The company's previous guidance was $ 355 - $ 385 million . Third quarter operating expenses were $ 59.9 million , compared to $ 61.6 million in the third quarter of 2020 , primarily due to the conclusion of our studies in ovarian and pancreatic cancer , partially offset by increased employee compensation expenses , commercial spending and increased preclinical activities . Cash and investments of $ 495.2 million at September 30 , 2021 reflects the acquisition in the third quarter of $ 28.0 million of Corcept common stock – 1.2 million shares pursuant to the company's stock repurchase program and 0.2 million shares in connection with the exercise of employee stock options . Over the term of the stock repurchase program , which began in November 2020 , Corcept acquired 4.3 million shares of common stock at a cost of $ 98.2 million . Clinical Development " Cortisol modulation has the potential to help treat many serious diseases , ” said Dr. Belanoff . “ Currently , our clinical programs are evaluating treatments for patients with solid tumors , non - alcoholic steatohepatitis ( NASH ) , antipsychotic - induced weight gain ( AIWG ) and Cushing's syndrome . We also continue to advance new cortisol modulators to the clinic . Early next year , we plan to start a Phase 2 trial in patients with amyotrophic lateral sclerosis ( ALS ) . "